The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies ...

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...

Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...

AstraZeneca Plc will invest $2.5 billion in a new research center in Beijing, in a major show of commitment to China just ...

AstraZeneca is investing $2.5bn in research and development and manufacturing in Beijing, as the drugmaker tries to move on after a scandal that led to the detention of a top executive in China .

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

AstraZeneca (AZN) stock in focus as the company invests $2.5B in Beijing for a new R&D center, strengthening its footprint in ...

The deal includes the Belgian biotech’s in-vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

AstraZeneca acquired the hypoparathyroidism therapy eneboparatide as part of a buyout of Amolyt Pharma in July 2024.

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global ...

AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma ...

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...